d-LSD binding to brain homogenates: possible relationship to serotonin receptors.
D004290:DOM 2,5-Dimethoxy-4-Methylamphetamine / Q000494:pharmacology; D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D001667:Binding, Competitive / Q000187:drug effects; D001921:Brain / Q000378:metabolism*; D001923:Brain Chemistry / Q000187:drug effects; D002540:Cerebral Cortex / Q000378:metabolism; D002746:Chlorpromazine / Q000494:pharmacology; D003533:Cyproheptadine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006213:Hallucinogens / Q000378:metabolism; D007099:Imipramine / Q000494:pharmacology; D008238:Lysergic Acid Diethylamide / Q000378:metabolism* / Q000494:pharmacology; D008297:Male; D008784:Methysergide / Q000494:pharmacology; D004130:N,N-Dimethyltryptamine / Q000494:pharmacology; D011398:Promethazine / Q000494:pharmacology; D011903:Raphe Nuclei / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D011955:Receptors, Drug; D011985:Receptors, Serotonin / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism / Q000494:pharmacology*; D013237:Stereoisomerism; D013347:Subcellular Fractions / Q000378:metabolism; D014316:Tritium
D006213:Hallucinogens; D011955:Receptors, Drug; D011985:Receptors, Serotonin; D014316:Tritium; D004290:DOM 2,5-Dimethoxy-4-Methylamphetamine; D003533:Cyproheptadine; D012701:Serotonin; D008238:Lysergic Acid Diethylamide; D011398:Promethazine; D007099:Imipramine; D002746:Chlorpromazine; D004130:N,N-Dimethyltryptamine; D008784:Methysergide